drugset / Trial / NCT04231279

Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

NCT04231279

Phase 3 Terminated 27 enrolled Orlando Health, Inc. ChiRhoClin, Inc. · collab
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This is a 3-year prospective study too identify the role of exocrine pancreatic insufficiency in patients with abdominal pain who are undergoing upper endoscopy. An endoscopic pancreatic function test (ePFT) with secretin will be performed in children undergoing routine investigative EGD. The goal of this study is to identify the role of exocrine pancreatic insufficiency in patients with abdominal pain who are undergoing upper endoscopy, who otherwise would be labelled as recurrent abdominal pain (RAP).

Timeline

Start
2022-01-28
Primary completion
2023-06-15
Completion
2023-06-15

Drugs

EvaluationDrugModalityDoseRoute
Background Secretin Other / unclassified